Indian scientists have developed a new technology platform that is capable of detecting Sars-Cov-2 by fluorescence readout. The platform can also be used to detect other DNA/RNA pathogens including HIV, influenza, HCV, Zika, Ebola, bacteria, and other mutating/evolving pathogens.
Scientists from Jawaharlal Nehru Centre for Advanced Scientific Research, along with scientists from IISc, have demonstrated a noncanonical nucleic acid-based G-quadruplex (GQ) topology targeted reliable conformational polymorphism (GQ-RCP) platform to diagnose Covid-19 clinical samples.
(Source: Pixabay)
New Delhi/India – A team of scientists has developed a new technology, platform for fluorometric detection of pathogens such as viruses by measurement of fluorescent light emitted. The potential of the new technology has been demonstrated for the detection of Sars-Cov-2. This technology platform can also be used to detect other DNA/RNA pathogens such as HIV, influenza, HCV, Zika, Ebola, bacteria, and other mutating/evolving pathogens.
Viruses are a major global threat to human health, and the ongoing Covid-19 pandemic caused by Sars-Cov-2 continues to inflict catastrophic effects on all aspects of our lives. The unprecedented transmission rate of RNA virus has necessitated the rapid and accurate diagnosis to facilitate contact tracing (prevent spreading) and to provide timely treatment.
Scientists from Jawaharlal Nehru Centre for Advanced Scientific Research, an autonomous institute of the Department of Science & Technology, Govt. of India, along with scientists from IISc (India Institute of Science), have demonstrated a noncanonical nucleic acid-based G-quadruplex (GQ) topology targeted reliable conformational polymorphism (GQ-RCP) platform to diagnose Covid-19 clinical samples. This work has been published recently in the journal ‘ACS Sensors’ and the team has also filed a patent for the novel technology.
The present work demonstrated the first GQ-targeted diagnostic platform for Sars-Cov-2 in clinical samples, based on a novel platform GQ-RCP. This molecular detection platform can be integrated into field-deployable isothermal amplification assays with more reliability and sequence specificity.
The platform lays greater emphasis on deciphering and systematic characterization of a unique set of interactions in nucleic acids to attain stable and reliable noncanonical DNA/RNA targets. The RCP-based target validation is a general and modular approach for the development of noncanonical nucleic acid-targeted diagnostic platforms for diverse pathogens, including bacteria and DNA/RNA viruses.
RT-q-PCR has been the gold standard for accurate detection of Sars-Cov-2 (Covid-19). Among the recent innovations on nucleic acid-targeted diagnosis of Sars-Cov-2, the techniques such as RT RPA and RT-Lamp use general-purpose DNA sensing probes. This increases the propensity of false-positive results arising out of unbiased detection of nonspecific amplification products. Recognizing unique DNA secondary conformations can be a promising solution to achieve reliable readouts.
The team has identified and characterized a unique G-quadruplex-based target derived from the 30 kb (kilobytes) genomic landscape of Sars-Cov-2 for specific detection of Sars-Cov-2. Unlike the other reliable diagnostic assays where the existing fundamental concepts have been repurposed, this work presents a completely novel strategy to target a unique, unconventional structure specific to the Sars-Cov-2 sequence using small molecule fluorophores (microscopic molecules).
The team developed GQ topology targeted detection of Sars-Cov-2 derived DNA obtained after reverse transcription and amplification from genomic RNA in clinical samples. The GQ targeted detection was achieved by pH-triggered facile transformation of the amplified double-stranded DNA into stable GQs, which forms the target for detection with remarkable selectivity using a designed fluorescent dye which is a benzobisthiazole-based target-specific turn on called BTMA. Thus, this study demonstrates a reliable strategy for fluorogenic organic molecule-based GQ-RCP platform to diagnose Covid-19 clinical samples and is the first practical demonstration of it.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
The team explains reliance on targeting unusual nucleic acid conformations in pathogens is an exciting approach to develop specific diagnostic assays with reliable read-outs. Molecular probes with superior conformation or sequences for specific recognition of nucleic acids would alleviate the challenge in existing techniques of eliminating false-positive detection results.
“We have demonstrated rational tailoring of molecular probes to achieve unambiguous target recognition and increase the reliability of detection, at a shorter time without requirement of expensive RT-q-PCR instrument. This RCP-based platform is very general and can be easily adopted for the detection of various DNA/RNA based pathogens including bacteria and viruses such as HIV, Influenza, HCV, etc.,” remarked T Govindaraju.